# Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)

> **NCT00760877** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 207 (actual)

## Conditions studied

- CHRONIC MYELOGENOUS LEUKEMIA

## Interventions

- **DRUG:** Nilotinib
- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT00760877
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2016-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00760877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00760877, "Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00760877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*